Prof. Alan Trounson will meet with senior biotech executives, business development leaders and investors to discuss the company’s technology and development program.
He will also be presenting at 3:45pm on Wednesday 7 June, detailing Cartherics’ pipeline, R&D activities, business objectives, and investment goals – with a view to engaging with potential investors and partners.
Cartherics’ portfolio includes an autologous CAR-T cell product scheduled to enter the clinic in 2024 for the treatment of ovarian cancer and an allogeneic immune cell platform consisting of CAR-iNK and CAR-iT cell products targeting solid tumours (ovarian, gastric and other cancers) derived from gene edited induced pluripotent stem cells (iPSCs).
The lead CAR-iNK product is expected to enter clinical trials in 2025.
“BIO is a special place to present for a biotech company because most of the industry is represented there, with great partnering opportunities and potential investment interests. It allows us to present our exciting immune therapies developments to the world,” said Prof. Trounson.
BIO Boston will bring thousands of global biotechnology and pharmaceutical leaders together, with the four-day, in-person event offering networking, programming and partnering opportunities.